Helen Blau American biochemist
Blau, Helen M.
בלאו, הלן
VIAF ID: 53353992 (Personal)
Permalink: http://viaf.org/viaf/53353992
Preferred Forms
-
- 100 1 _ ‡a Blau, Helen M.
- 100 1 _ ‡a Blau, Helen M.
-
- 100 1 _ ‡a Blau, Helen M.
- 100 1 _ ‡a Blau, Helen M. (sparse)
- 100 0 _ ‡a Helen Blau ‡c American biochemist
-
4xx's: Alternate Name Forms (10)
Works
Title | Sources |
---|---|
Handbook of stem cells. Volume 2, Adult and fetal | |
Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia. | |
MicroRNA programs in normal and aberrant stem and progenitor cells. | |
Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients | |
Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-gamma | |
mRNA translation is not a prerequisite for small interfering RNA-mediated mRNA cleavage | |
Muscle gene expression in heterokaryons | |
Muscling toward therapy with ERBB3 and NGFR | |
The myoblast defect identified in Duchenne muscular dystrophy is not a primary expression of the DMD mutation. Clonal analysis of myoblasts from five double heterozygotes for two X-linked loci: DMD and G6PD. | |
Myoblast-mediated expression of colony stimulating factor-1 (CSF-1) in the cytokine-deficient op/op mouse | |
Myoblasts and macrophages share molecular components that contribute to cell-cell fusion | |
Nanogel star polymer architectures: a nanoparticle platform for modular programmable macromolecular self-assembly, intercellular transport, and dual-mode cargo delivery | |
Neural cell adhesion molecule (NCAM) and myoblast fusion | |
Neuromuscular development and disease | |
NKX3-1 is required for induced pluripotent stem cell reprogramming and can replace OCT4 in mouse and human iPSC induction | |
Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation | |
Non-invasive intravital imaging of cellular differentiation with a bright red-excitable fluorescent protein | |
Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. | |
Noninvasive Tracking of Quiescent and Activated Muscle Stem Cell (MuSC) Engraftment Dynamics In Vivo. | |
Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation | |
Nuclear reprogramming in heterokaryons is rapid, extensive, and bidirectional | |
Nuclear reprogramming to a pluripotent state by three approaches | |
Objective comparison of particle tracking methods | |
Optimizing techniques for tracking transplanted stem cells in vivo. | |
Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis | |
Perspective for special Gurdon issue for differentiation: can cell fusion inform nuclear reprogramming? | |
Perturbation of single hematopoietic stem cell fates in artificial niches | |
Plasticity of the differentiated state | |
Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy | |
Prostaglandin E2 is essential for efficacious skeletal muscle stem-cell function, augmenting regeneration and strength | |
Protein-engineered biomaterials to generate human skeletal muscle mimics. | |
Protein-protein interactions monitored in mammalian cells via complementation of beta -lactamase enzyme fragments | |
Publisher Correction: High-resolution myogenic lineage mapping by single-cell mass cytometry. | |
Purification and proliferation of human myoblasts isolated with fluorescence activated cell sorting | |
Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette | |
Re"evolutionary" regenerative medicine | |
Redefining differentiation: Reshaping our ends | |
Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium | |
Rejuvenation of the muscle stem cell population restores strength to injured aged muscles | |
Reprogramming cell differentiation in the absence of DNA synthesis | |
Reprogramming to a muscle fate by fusion recapitulates differentiation | |
Reprogramming towards pluripotency requires AID-dependent DNA demethylation | |
Restriction enzyme-generated siRNA (REGS) vectors and libraries | |
Retroviral lineage markers for assessing myoblast fate in vivo | |
Reversibility of Defective Hematopoiesis Caused by Telomere Shortening in Telomerase Knockout Mice | |
RIP2, a checkpoint in myogenic differentiation | |
Self-renewal and expansion of single transplanted muscle stem cells | |
Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice | |
Significant differences among skeletal muscles in the incorporation of bone marrow-derived cells | |
Simultaneous silencing of multiple RB and p53 pathway members induces cell cycle reentry in intact human pancreatic islets | |
Single-cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments. | |
Sir John Gurdon: father of nuclear reprogramming | |
skNAC, a Smyd1-interacting transcription factor, is involved in cardiac development and skeletal muscle growth and regeneration | |
Something in the eye of the beholder. | |
Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy | |
Spectrophotometric quantitation of tissue culture cell number in any medium | |
Stable reprogrammed heterokaryons form spontaneously in Purkinje neurons after bone marrow transplant | |
Stem-cell fusion: A twist of fate | |
Stem Cells and Aging: What's Next? | |
Stem Cells in the Treatment of Disease | |
Stem cells to the rescue, 2024: | |
Steroids induce acetylcholine receptors on cultured human muscle: implications for myasthenia gravis | |
Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors | |
Structure-function analysis of varicella-zoster virus glycoprotein H identifies domain-specific roles for fusion and skin tropism | |
Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture | |
Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. | |
Tamoxifen treatment ameliorates contractile dysfunction of Duchenne muscular dystrophy stem cell-derived cardiomyocytes on bioengineered substrates | |
Telomere shortening is a hallmark of genetic cardiomyopathies | |
Tet B or not tet B: advances in tetracycline-inducible gene expression | |
Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16. | |
Tetracycline-regulated gene expression following direct gene transfer into mouse skeletal muscle | |
Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB. | |
Tissue Stem Cells: Architects of Their Niches | |
Toxoplasma secreting Cre recombinase for analysis of host-parasite interactions | |
Transcriptional control: rheostat converted to on/off switch | |
Transient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells | |
Transient immunosuppressive treatment leads to long-term retention of allogeneic myoblasts in hybrid myofibers | |
Transient inactivation of Rb and ARF yields regenerative cells from postmitotic mammalian muscle | |
Transient production of alpha-smooth muscle actin by skeletal myoblasts during differentiation in culture and following intramuscular implantation | |
Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases | |
Tumor suppression by RNA from the 3' untranslated region of alpha-tropomyosin | |
Tumor suppressors: enhancers or suppressors of regeneration? | |
Turning terminally differentiated skeletal muscle cells into regenerative progenitors. | |
VEGF gene delivery for treatment of ischemic cardiovascular disease | |
The well-tempered vessel |